A retrospective, case-control study (26 patients with IgE >700 IU/mL and 26 with IgE 30–700 IU/mL) found that omalizumab was equally safe and effective in reducing corticosteroid use, asthma symptoms and emergency department visits in patients with severe asthma and IgE levels >700 IU/mL (mean, 2371 IU/mL) than those with IgE levels 30–700 IU/mL (mean, 221 IU/mL). The gene discussed is IGHE; the disease is asthma.